Core Viewpoint - The return of the original brand Mucosolvan (Ambroxol Hydrochloride) to the Chinese market is anticipated in December 2025, following its exit due to registration expiration and increased competition from generic drugs [1][2]. Group 1: Company Background - Mucosolvan was originally developed by Boehringer Ingelheim and launched in Germany in 1978, entering the Chinese market in 1991 [2]. - The product achieved peak sales exceeding 8 billion yuan in China, making it a highly competitive product in the market [2]. - The original manufacturer, Boehringer Ingelheim, ceased the product's registration in China in 2020, leading to its market exit [3]. Group 2: Market Competition - The return of Mucosolvan will face competition from 367 similar drug approvals in China, including significant price competition from generics [6]. - In the 2021 centralized procurement, Boehringer Ingelheim's bid was only a 0.3% price reduction, while competitors like Yunnan Longhai offered a 93.3% reduction [4]. - The market for expectorants is crowded, with other active ingredients available, such as bromhexine and acetylcysteine, which may affect Mucosolvan's market share [6]. Group 3: Future Outlook - The product's return is now under the management of Opella, a company that became independent from Sanofi in May 2025, which retains a 48.2% stake in Opella [4]. - The ability of Mucosolvan to regain consumer trust and willingness to pay a premium in a low-price environment remains uncertain [6]. - The performance of Mucosolvan post-return will be closely monitored, especially regarding its positioning in the OTC market [6].

Group 1: Guizhou Moutai - Guizhou Moutai achieved a net profit of 45.403 billion yuan in the first half of 2025, an increase of 8.89% year-on-year [1] - The company's operating income for the same period was 89.389 billion yuan, reflecting a growth of 9.1% year-on-year [1] - Basic earnings per share were reported at 36.18 yuan per share [1] Group 2: Weixing New Materials - Weixing New Materials reported a net profit of 271 million yuan in the first half of 2025, a decrease of 20.25% year-on-year [1] - The company's operating income was 2.078 billion yuan, down 11.33% year-on-year [1] - The company plans to distribute a cash dividend of 1 yuan per 10 shares [1] Group 3: Jianyuan Trust - Jianyuan Trust's net profit for the first half of 2025 was 40.2897 million yuan, an increase of 13.36% year-on-year [1] - The company achieved an operating income of 15 million yuan, a significant growth of 84.89% year-on-year [1] - Basic earnings per share were reported at 0.0041 yuan per share [1][2] Group 4: Weili - Weili won a bid for a leachate treatment project, expected to generate an annual revenue of approximately 61 million yuan [1] - The project has a total expected revenue of about 610 million yuan over a 10-year operational period [1] - The project includes a 0.5-year construction period followed by a 10-year operational period [1] Group 5: Tianjun Wind Power - Tianjun Wind Power provided a guarantee for a credit line of 150 million yuan for its wholly-owned subsidiary [1] - The guarantee covers the principal amount, interest, penalties, and other related costs [1] - The guarantee period is three years from the maturity of the main contract [1] Group 6: Jiangshan Oupai - Jiangshan Oupai's wholly-owned subsidiary completed the registration for a change in business type [1] - The subsidiary is now classified as a limited liability company [1] Group 7: Ningbo Port - Ningbo Port announced the resignation of independent director Yan Guoqing due to personal reasons [1] Group 8: Yangfan New Materials - Yangfan New Materials reported a net profit of 23.1372 million yuan in the first half of 2025, marking a turnaround from losses [1] - The company's total operating revenue was 473 million yuan, an increase of 47.93% year-on-year [1] Group 9: Zhongguancun - Zhongguancun's subsidiary received a drug registration certificate for a new injection [1] - The company also announced that another product passed the consistency evaluation for generic drugs [1] Group 10: Hengtong Oriental - Hengtong Oriental is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [1] Group 11: Quzhou Development - Quzhou Development plans to acquire 95.46% of Xian Dao Electronics and will resume trading on August 13, 2025 [1] Group 12: Jiangsu Sop - Jiangsu Sop reported a net profit of 102 million yuan in the first half of 2025, a decrease of 13.01% year-on-year [1] - The company's operating income was 3.158 billion yuan, down 1.08% year-on-year [1] Group 13: Fudan Fuhua - Fudan Fuhua's subsidiary plans to invest 48.87 million yuan in a capital increase for another company [1] Group 14: Shaanxi Huada - Shaanxi Huada is planning to acquire 100% of Huajing Microelectronics and has suspended trading [1]

Core Viewpoint - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. announced that its subsidiary, Duoduo Pharmaceutical, has successfully passed the consistency evaluation for Tramadol Hydrochloride Injection, enhancing its market competitiveness and operational performance [1][5]. Group 1: Drug Approval and Details - Duoduo Pharmaceutical received the approval notice for Tramadol Hydrochloride Injection (2ml:100mg) from the National Medical Products Administration [1][2]. - The drug is classified as a chemical drug and is indicated for moderate to severe pain [3][4]. - The consistency evaluation approval allows for changes in the drug formulation, production process, and quality standards [2][4]. Group 2: Market Context and Financial Impact - In 2024, the sales revenue of Tramadol Hydrochloride Injection in domestic sample hospitals was 230 million yuan, with 93 million yuan in the first quarter of 2025 [4]. - Duoduo Pharmaceutical is the sixth company to pass the consistency evaluation for this drug, following five other companies [4]. - The company has invested 7.15 million yuan in research and development for this drug's consistency evaluation project [4]. Group 3: Future Prospects - The approval of Tramadol Hydrochloride Injection is expected to improve the company's market position and operational results [5]. - The company emphasizes the importance of drug research and development, maintaining strict quality control throughout the drug lifecycle [5].

（文章来源：证券日报） 证券日报网讯 8月12日晚间，中关村发布公告称，近日，公司下属公司多多药业收到国家药品监督管理 局核准签发的《药品注册证书》，获悉，多多药业研制的"盐酸氨溴索注射液"通过了药品注册审评审 批。 ...

盐酸氨溴索具有促进粘液排除作用及溶解分泌物的特性，可促进呼吸道内粘稠分泌物的排除及减少粘液 的滞留，因而促进排痰，改善呼吸状况。盐酸氨溴索注射液临床适用于伴有痰液分泌不正常及排痰功能 不良的急性、慢性肺部疾病。例如慢性支气管炎急性加重、喘息型支气管炎及支气管哮喘的祛痰治疗。 手术后肺部并发症的预防性治疗。早产儿及新生儿的婴儿呼吸窘迫综合症(IRDS)的治疗。 截至公告披露日，盐酸氨溴索注射液仿制药注册申请项目公司已累计投入研发费用205.58万元。 格隆汇8月12日丨中关村(000931.SZ)公布，近日，公司下属公司多多药业有限公司(简称：多多药业)收 到国家药品监督管理局核准签发的《药品注册证书》(证书编号：2025S02440)，获悉，多多药业研制 的"盐酸氨溴索注射液"(规格：2ml:15mg)通过了药品注册审评审批。 ...

Core Viewpoint - The company, Zhongguancun, announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration certificate of Ambroxol Hydrochloride Injection, which is expected to aid in respiratory health [1] Group 1 - The approved drug, Ambroxol Hydrochloride, is known for its properties that promote mucus clearance and dissolve secretions, thereby improving respiratory conditions [1] - The future production and sales of the drug may face uncertainties due to factors such as national policies and market environment [1]

Core Viewpoint - The company Zhongguancun (000931.SZ) announced that its subsidiary Duoduo Pharmaceutical Co., Ltd. has received the drug registration certificate for "Ambroxol Hydrochloride Injection" from the National Medical Products Administration, indicating successful approval for the drug's registration review and approval process [1] Group 1: Product Details - Ambroxol Hydrochloride has properties that promote mucus clearance and dissolve secretions, aiding in the expulsion of viscous secretions from the respiratory tract and improving respiratory conditions [1] - The injection is clinically applicable for abnormal mucus secretion and poor expectoration function in acute and chronic pulmonary diseases, such as acute exacerbation of chronic bronchitis, asthmatic bronchitis, and bronchial asthma [1] - It is also indicated for the preventive treatment of pulmonary complications after surgery and for the treatment of infant respiratory distress syndrome (IRDS) in premature and newborn infants [1] Group 2: Financial Investment - As of the announcement date, the company has invested a total of 2.0558 million yuan in the research and development of the generic drug registration application project for Ambroxol Hydrochloride Injection [1]

Core Viewpoint - The 90th National Pharmaceutical Trade Fair showcased Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., highlighting its brand, high-value product matrix, and ecological win-win philosophy [3][4] Group 1: Product Showcase - Zhenbaodao Pharmaceutical exhibited high-quality product lines focusing on cardiovascular, respiratory, and anti-infection treatment areas, including key products like Injection Blood Setong 100mg and Xuechuang Capsule [3] - The company has developed a dual-driven system of "Traditional Chinese Medicine + Chemical Medicine," featuring products such as Compound Qilan Oral Liquid and Injection Ammonium Bromide [3] Group 2: Marketing Strategy - The company emphasized its 2025 "Guangshen Tuo" marketing strategy, which segments regional markets based on product attributes and promotes a model of "recruiting merchants, finding merchants, and servicing merchants" to enhance terminal coverage and sales efficiency [4] - Zhenbaodao Pharmaceutical established a three-tier academic promotion system, integrating medical, market, and data teams to monitor industry trends and provide precise marketing strategies [4] Group 3: Collaborative Ecosystem - The participation in the trade fair demonstrated the company's competitive product pipeline and industrial layout, aiming to build a comprehensive ecosystem of strategic collaboration, resource sharing, and value co-creation [4] - The company plans to continue driving innovation and collaboration, positioning itself to lead the pharmaceutical industry towards higher value creation [4]